This announcement is a separate document:
サンバイオ：主要開発品SB623を用いた慢性期脳梗塞の細胞治療に関する米国での新規特許のお知らせ
SanBio: Announcements of individual stocks: New patents related to the cell treatment of chronic cerebral infarction using the main development product SB623 have been issued in the United States.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated